US Pharma MarketingGSK strikes deal for Chimagen’s T cell engager for blood cancer
GSK inks up to $750M deal for Chimagen Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power…
Two years after GSK announced its first licensing pact with Chimagen Biosciences, the UK drugmaker is making a new deal with the Chinese company for a trispecific T cell engager that it ...
Source: Endpoints News